Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

The chief commercial officer at Form Health advises benefit managers to take a close look at vendors and employee needs to ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states ...

GLP-1 RA use was associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

Starting Jan. 1, Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 ...

The nation’s largest Medicaid program could eliminate coverage of GLP-1 drugs for weight loss. A proposed budget published by California Gov. Gavin Newsom would eliminate coverage for GLP-1 drugs for ...

The best. Even though it’s got a lot of chocolate in it, which doesn’t make much sense to me because chocolate’s supposed to be something that’s really been attacked by the GLP-1s.